Recently, the first clinical study to use HER2-specific CAR-T cells in patients with HER2-positive sarcoma showed that the HER2-directed CAR approach performed well with respect to safety and efficacy (ORR, 7/17) (Ahmed et al., 2015). The gene discussed is ERBB2; the disease is sarcoma.